advertisement
Abstract #19791 Published in IGR 9-4
Five years retrospective study of latanoprost glaucoma treatment
Zavorkova M; Susicky PČeska a Slovenska Oftalmologie 2007; 63: 292-298
AIM: The authors evaluated their five years experience with 0.005% latanoprost (Xalatan) glaucoma treatment. They monitored the latanoprost efficiency to lower the intraocular pressure (IOP) and its capability to maintain the target IOP in the long term. PATIENTS AND METHOD: The group consisted of 118 patients (231 eyes) who are treated for glaucoma with latanoprost. The follow up period was at least three years. The patients were checked each three months and the results of the IOP measurement for the study purpose were included once a year. RESULTS: The IOP before the latanoprost treatment was 23.4 ± 5.3 mmHg. The IOP after one-year latanoprost treatment was 17.6 ± 3.2 mmHg; after two years 17.7 ± 3.9 mmHg; after three years 17.1 ± 3.1 mmHg; after four years 17.1 ± 3.2 mmHg; and after five years 17.6 ± 3.8 mmHg. The average IOP during the latanoprost treatment was 17.4 ± 3.4 mmHg, the average lowering of the IOP after the start of the latanoprost treatment was by 6.0 mmHg. The IOP lowering by 30% against the IOP value at the time of glaucoma diagnose was reached after three years in 82% (189 out of 231) eyes, after five years in 83% (54 out of 65) eyes. CONCLUSION: Our five-years experience confirmed that latanoptost is a drug significantly lowering and in the long term maintaining the IOP level. As a great advantage, we appreciate the simple application and good compliance. LA: Czech
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
